News

The CHMP recommends the approval of TYSABRI for use as a disease modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS) patients with highly active disease activity despite a

AP32788 targets tumors driven by EGFR or HER2 kinases and was designed to achieve selective inhibition of these kinases with exon 20 mutations. There are currently no approved

The agreement enables CFFT to use ChemDiv’s unique chemistry platform to advance promising scientific research in the field of cystic fibrosis (CF) treatment. This collaboration allows ChemDiv to

"In the first ever comparative Phase 3 head-to-head study of two proteasome inhibitors in relapsed multiple myeloma, Kyprolis in combination with dexamethasone nearly doubled progression-free survival compared to

The data included in the application support the use of Epclusa (SOF/VEL) in adults with all genotypes (GT1-6) of HCV infection. The CHMP positive opinion was adopted following

The milestone payment was triggered by the initial commercial sale of Darzalex in Europe. Earlier this month, the European Commission granted conditional approval to Darzalex to treat adults

The patient will be treated at University Hospital Germans Trias i Pujol in Badalona, Barcelona, Spain. Abivax will undertake the trial at clinical centers in Spain and Belgium,

Flixabi is now approved to treat rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. Flixabi demonstrated comparable safety and equivalent efficacy to Remicade in

Checkpoint will develop and commercialize these small molecule inhibitors in solid tumors. The BET inhibitor program is the subject of an exclusive, worldwide license agreement pursuant to which